Spinal Muscular Atrophy

Slide 1 · Spinal Muscular Atrophy

Molecular pathogenesis, neurogenic morphology, clinical variation, and mechanism-based therapy

Pathology teaching lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Identify the specific neuronal population affected in 5q-associated SMA.

Explain how SMN1 loss and SMN2 splicing interact to alter SMN protein availability.

Interpret neurogenic muscle morphology using denervation and compensatory reinnervation.

Distinguish textbook-described clinical phenotypes and molecular therapeutic strategies.

Slide 3 · SMA is a disorder of lower motor neuron survival

A group of genetically related childhood disorders, rather than a primary myofiber degeneration.

Marked lower motor neuron loss produces progressive muscle weakness and atrophy.

The most common forms involve the chromosome 5q SMN gene system.

The extent and timing of neuron loss shape the clinical phenotype.

Slide 4 · Where does the primary lesion occur?

Neural compartment

Muscle compartment

Lower motor neurons are the primary degenerating cells.

Reduced innervation deprives skeletal myofibers of normal neural input.

Residual neurons may innervate surviving muscle fibers.

Atrophy is a downstream consequence of lost motor neuron input.

Compensatory fiber hypertrophy can coexist with extensive atrophy.

Muscle morphology therefore records a neurogenic process.

Slide 5 · Motor units connect neuronal loss to muscle atrophy

A motor unit comprises one motor neuron, its axon, and the myofibers it innervates.

Intact

Lost

Intact

Remaining units retain innervation

Lost unit → denervation → atrophy

Schematic; Not anatomical scale.

Slide 6 · Motor neuron depletion produces a cascade of tissue effects

Lower motor neuron loss

Reduced motor units

Muscle denervation

Myofiber atrophy

The sequence accounts for weakness without requiring primary degeneration of the myofiber itself.

Schematic causal model based on Robbins Chapters 27–28.

Slide 7 · Why the term “spinal muscular atrophy” can mislead

“Muscular atrophy” describes the downstream muscle phenotype.

For 5q-SMA, the primary disease target is the lower motor neuron.

A muscle biopsy may reveal denervation, not a primary structural myopathy.

The genetic defect is upstream of both neuronal loss and myofiber atrophy.

Slide 8 · Genetic architecture of the common 5q forms

The common disease-associated locus lies on chromosome 5q.

SMN1 normally provides most of the functional SMN protein.

The adjacent SMN2 gene has similar sequence but different transcript processing.

Clinical variability reflects, in important part, how much residual SMN can be produced.

Slide 9 · 5q-SMA is inherited in an autosomal recessive pattern

5q-SMA as an autosomal recessive SMN1 loss-of-function disorder.

A disease genotype results when both relevant SMN1 alleles fail to provide adequate function.

Heterozygous carriers are a key family-counselling concept.

Allelic segregation and clinical severity are distinct questions: SMN2 modifies phenotype.

Slide 10 · Autosomal recessive SMA: Inheritance logic

Illustrative cross: Two heterozygous carrier parents

SMN1 / SMN1

Unaffected non-carrier

SMN1 / variant

Unaffected carrier

Variant / SMN1

Unaffected carrier

Variant / variant

Affected genotype

Expected genotypic proportions: 1 : 2 : 1 for each pregnancy; Illustrative Mendelian model.

Slide 11 · Robbins-reported incidence: Approximately 1 in 6000 births

The chapter on skeletal muscle reports an incidence of 1 in 6000 births.

This figure describes the textbook source, not a country-specific surveillance estimate.

Population incidence does not determine the severity of an individual affected child.

Avoid confusing disease incidence with carrier frequency or recurrence probability.

Slide 12 · SMN1 is the main source of survival motor neuron protein

SMN1 gene

RNA transcript

Functional SMN protein

Motor neuron homeostasis

Loss-of-function variants in SMN1 diminish the dominant source of SMN protein.

SMN function to spliceosome assembly and ribonucleoprotein biogenesis.

Slide 13 · The SMN protein participates in spliceosome assembly

The spliceosome is the RNA-processing machinery relevant to removal of introns.

SMN as participating in spliceosome assembly.

Loss of SMN has consequences beyond a single downstream gene.

This mechanistic role explains why an RNA-processing protein can be central to a neurogenic disorder.

Slide 14 · SMN function extends into ribonucleoprotein biology

SMN availability

RNP biogenesis

RNA-associated cellular processes

Motor neuron maintenance

The source also links SMN1 to ribonucleoprotein biogenesis and neuronal homeostasis.

This diagram summarizes roles named in Chapter 27; It does not specify unreported downstream effectors.

Slide 15 · Selective motor neuron vulnerability is a separate question

SMN supports fundamental cellular RNA-associated machinery.

The phenotype nevertheless prominently involves lower motor neurons.

The supplied Robbins extract does not establish one complete molecular explanation for that selectivity.

Do not invent a precise downstream death pathway when the source does not give one.

Slide 16 · SMN1 and SMN2: Similar genes, different RNA outputs

SMN1 transcript

Predominant functional SMN output

Relatively stable SMN protein

SMN2 transcript

Altered mRNA splicing

Unstable SMN isoform → rapid degradation

A few sequence differences change splicing; SMN2 only partly compensates for loss of SMN1.

Slide 17 · SMN1 and SMN2 are adjacent but not interchangeable

A few base-pair differences distinguish SMN2 from SMN1.

Those differences alter SMN2 mRNA splicing.

The altered SMN2 transcripts preferentially yield an unstable protein isoform.

Thus gene similarity does not imply equal functional protein output.

Slide 18 · SMN2 sequence differences shift the protein outcome

Sequence differences

Altered splicing

Unstable SMN isoform

Rapid degradation

Compared with SMN1, SMN2 supplies less stable functional SMN protein per copy.

Slide 19 · Why SMN2 cannot fully replace SMN1

SMN1 output

SMN2 output

Most SMN protein ordinarily derives from SMN1 transcripts.

Functional protein supports critical RNA-processing functions.

Loss of SMN1 removes the major source of SMN.

SMN2 transcripts have altered splicing due to sequence variation.

A substantial output is an unstable isoform rapidly degraded.

Residual output influences the disease phenotype.

Slide 20 · SMN2 exhibits copy-number variation

Robbins explicitly identifies SMN2 as a copy-number-variable gene.

Even unaffected individuals may carry one or multiple copies per chromosome 5.

The number of SMN2 copies varies independently of whether SMN1 is dysfunctional.

Copy number is a biologic modifier, not the causal SMN1 lesion.

Slide 21 · The modifier model: SMN1 lesion plus SMN2 dosage

SMN1 loss

Residual SMN2 output

Total functional SMN

Clinical severity

Variation in SMN2 copy number helps explain differing phenotypes among people with 5q-SMA.

Qualitative relationship only; The Robbins excerpt supplies no exact copy-number classification.

Slide 22 · SMN2 copy number is not itself a diagnosis

The causal criterion within the supplied source is loss-of-function of SMN1.

SMN2 is relevant because it modifies available SMN after SMN1 function is lost.

A modifier must not be mistaken for an independent causative genotype.

Exact SMN2 thresholds for clinical subtypes are not provided in the cited extract.

Slide 23 · SMN1 loss-of-function is the unifying 5q lesion

All 5q-SMA forms to loss-of-function mutations in SMN1.

Deletion is described as the usual mutation class.

Different clinical expressions do not require unrelated primary genes.

Residual SMN biology helps connect a common lesion to a phenotypic spectrum.

Slide 24 · Causal lesion and modifier: Do not conflate them

Feature

SMN1

SMN2

Principal role

Major functional SMN source

Alternative SMN source

Disease relation

Loss-of-function causes 5q-SMA

Copy number helps modify phenotype

Transcript behavior

Produces predominant SMN output

Splicing favors unstable isoform

Teaching point

Establish the upstream defect

Interpret variation in residual output

Slide 25 · One integrated molecular model of 5q-SMA

SMN1 loss

Lower SMN availability

Lower motor neuron loss

Denervation and atrophy

SMN2 transcript output modifies the amount of residual functional protein upstream of neuron loss.

Slide 26 · A genetic lesion can have prenatal morphologic consequences

Motor neuron loss associated with SMN1 deficiency may begin in utero.

Some muscle fibers may therefore never receive normal initial innervation.

Others may lose innervation after the motor unit is initially established.

Both mechanisms can converge on a similar pattern of severe myofiber atrophy.

Slide 27 · Two routes to a denervated muscle fiber

Failure of initial innervation

Loss of established innervation

Motor neurons may be lost early in development.

A subset of developing fibers may lack appropriate innervation.

The resulting fibers remain markedly small.

Previously innervated fibers lose their input.

Denervation reduces trophic and functional support.

Remaining motor neurons can partly compensate.

Slide 28 · Denervation translates neuronal loss into muscle pathology

Motor neuron dropout

Loss of innervation

Myofiber size decline

Neurogenic atrophy

The sequence is a tissue-level consequence of neuronal loss rather than a primary myofiber metabolic defect.

Slide 29 · The motor unit organizes muscle fiber phenotype

Each muscle fiber belongs to a motor unit supplied by a particular motor neuron.

Muscle fiber type reflects the identity of its innervating motor neuron.

Loss and regrowth of innervation can therefore change the arrangement of fiber types.

The motor-unit concept explains fiber-type grouping after reinnervation.

Slide 30 · Reinnervation can enlarge surviving motor units

Motor neuron loss

Denervated fibers

Collateral innervation by survivors

Larger residual motor units

Surviving axons can capture fibers that formerly belonged to different motor units.

Slide 31 · Compensatory hypertrophy is not primary fiber growth

Normal or hypertrophied fibers amid extensive infantile SMA atrophy.

These preserved large fibers receive innervation from surviving motor neurons.

Their size contrasts with the numerous denervated atrophic fibers.

The juxtaposition reflects unequal survival of motor-unit input.

Slide 32 · Severe infantile SMA: Rounded atrophy and surviving fibers

Schematic normal mosaic

Schematic SMA pattern

Relatively uniform myofiber calibers

Many small rounded fibers; Rare large survivors

Original conceptual schematic; Not histopathology or scale-preserving.

Slide 33 · Severe infantile SMA has a distinctive muscle pattern

Large zones of severely atrophic round myofibers are described.

Scattered normal-caliber or hypertrophied fibers appear singly or in small groups.

The larger fibers reflect retained or regained neuronal innervation.

The finding is descriptive; The source excerpt does not make biopsy alone a molecular confirmation.

Slide 34 · Infantile SMA morphology versus generic neurogenic change

Classic neurogenic atrophy

Severe infantile SMA

Denervated fibers often become angular or flattened.

Reinnervation may produce fiber-type grouping.

Loss of an enlarged unit may generate grouped atrophy.

Many severely small fibers may be rounded.

Scattered normal or hypertrophied fibers remain.

Loss of initial developmental innervation can contribute.

Slide 35 · Why rounded atrophic fibers can occur in infantile SMA

If initial innervation never becomes established, muscle-fiber development is affected early.

The source explicitly describes very small rounded fibers in severe infantile SMA.

This appearance differs from the classic angular profile often seen after denervation.

Shape is a morphologic clue, not a stand-alone molecular mechanism or diagnosis.

Slide 36 · Fiber-type grouping follows successful collateral reinnervation

A surviving motor axon can innervate fibers that previously belonged to other units.

Because the innervating neuron influences muscle-fiber type, neighboring fibers may become uniform in type.

Reinnervation can generate larger-than-normal motor units.

Fiber-type grouping therefore signals adaptation to prior denervation.

Slide 37 · Grouped atrophy can follow subsequent unit failure

Reinnervated large unit

New neuronal or axonal loss

Many linked fibers denervated

Grouped atrophy

A compensatory enlargement of motor units can create clusters of fibers vulnerable to a later shared loss of input.

Slide 38 · Neurogenic versus primary myopathic injury

Neurogenic mechanism

Primary myopathic mechanism

Loss of neuron/axon disrupts neural support.

Atrophy and reinnervation are central tissue processes.

Grouping phenomena relate to motor unit reorganization.

Direct myofiber injury may cause segmental degeneration.

Myophagocytosis and regeneration follow necrosis.

Damage can release muscle enzymes such as creatine kinase.

Slide 39 · Reading a hypothetical muscle specimen

Finding

Mechanistic interpretation

Important limitation

Small rounded fibers with rare large fibers

Infantile SMA-type denervation pattern

Not molecular confirmation

Angular atrophic fibers

Denervation of established motor units

Not specific for SMA

Fiber-type grouping

Collateral reinnervation

Requires appropriate fiber typing

Segmental fiber necrosis

Primary myofiber injury mechanism

Supports another process

Slide 40 · A morphology-first diagnostic argument has limits

Neurogenic muscle changes support denervation but do not uniquely identify its cause.

Motor neuron disorders, radiculopathy, and neuropathy can also produce neurogenic atrophy.

The distinctive infantile SMA pattern is interpreted within clinical and molecular context.

Specific SMN1 analysis addresses disease identity more directly than fiber shape alone.

Slide 41 · Clinical expression reflects the extent and timing of neuron loss

The disease causes progressive weakness through lower motor neuron depletion.

Earlier and more severe neuronal involvement is associated with more severe phenotype.

Later-onset forms typically evolve more gradually description.

The supplied source does not establish a single predicted course for every treated patient.

Slide 42 · 5q-SMA forms vary in age of onset and clinical trajectory

Earlier onset

Type I / Werdnig–Hoffmann

First year of life; Most severe common form

Later onset

Other 5q-SMA variants

More gradual course

Childhood–adolescence

Type III / Kugelberg–Welander

Motor disability emerges later

Slide 43 · SMA type I: The severe infantile form

The most common severe 5q-associated phenotype is termed SMA type I.

The historical eponym Werdnig–Hoffmann disease refers to this phenotype.

Onset occurs during the first year of life description.

Its severity is consistent with early and extensive loss of lower motor neuron input.

Slide 44 · Type I survival figures are historical textbook descriptions

Untreated or historical severe type I disease as usually fatal by age 2.

The same source discusses gene and splice-modifying treatments that change therapeutic possibilities.

Do not automatically apply historical natural-history outcomes to an individual receiving modern treatment.

This lecture supplies no contemporary treatment-stratified survival estimates.

Slide 45 · Later-onset SMA forms constitute a clinical spectrum

The same SMN1-related disease mechanism can present later in childhood.

Later-onset forms as having a more gradual course.

The rate and timing of disability are important phenotypic distinctions.

Copy-number-dependent residual SMN provides a molecular explanation for much of this variation.

Slide 46 · SMA type III: Kugelberg–Welander phenotype

SMA type III is identified as the Kugelberg–Welander disease phenotype.

Motor disability usually becomes apparent during later childhood or adolescence.

Its course is described as more gradual than severe infantile disease.

The source does not assign an exact SMN2 copy count to this clinical label.

Slide 47 · Clinical phenotypes explicitly

Phenotype

Onset

Course

SMA type I (Werdnig–Hoffmann)

First year of life

Severe; historically usually fatal by age 2

Other later-onset 5q-SMA

Later than severe infantile form

More gradual progression

SMA type III (Kugelberg–Welander)

Later childhood/adolescence

Motor disability usually develops later

Slide 48 · Phenotype must not be inferred from the gene name alone

SMN1 loss-of-function explains the common molecular origin.

SMN2 dosage affects residual SMN and contributes to clinical variation.

Timing of disease and observable motor function are separate clinical dimensions.

Treatment can complicate comparison with historical untreated categories.

Slide 49 · A pathology-based diagnostic reasoning sequence

Progressive weakness

Evidence of neurogenic disorder

Suspect 5q-SMA

Evaluate SMN1 status

SMN2 copy number then helps interpret phenotypic variability rather than replacing assessment of SMN1.

Conceptual reasoning aid, not a substituted clinical practice guideline.

Slide 50 · Molecular assessment: Distinguish detection from modification

SMN1 loss-of-function is the etiologic finding described for 5q-SMA.

SMN2 copy-number variation supplies modifier information.

A plausible molecular workflow separates causal SMN1 analysis from SMN2 dosage characterization.

The provided Robbins excerpt does not specify assay platform, sensitivity, or official testing algorithm.

Slide 51 · Causative, modifying, and morphologic evidence

Genetic evidence

Pathologic evidence

SMN1 loss-of-function: Explanatory disease lesion.

SMN2 copy number: Phenotype modifier.

Gene identity and gene dosage should be reported distinctly.

Lower motor neuron loss: Primary target.

Neurogenic muscle atrophy: Downstream manifestation.

Hypertrophied survivors: Compensatory adaptation.

Slide 52 · Distinguishing adjacent motor neuron diseases

Feature

5q spinal muscular atrophy

Kennedy disease

Genetics

Autosomal recessive; SMN1 loss

X-linked; androgen receptor CAG expansion

Mechanism

Reduced SMN protein

Polyglutamine-repeat disease

Clinical emphasis

Childhood weakness; severity spectrum

Distal amyotrophy and bulbar signs

Additional features

SMN2 modifies phenotype

Androgen insensitivity and endocrine signs

Slide 53 · How SMA differs from classic ALS framing

5q-SMA

ALS

Genetically linked childhood forms.

Lower motor neuron loss is the defining lesion here.

SMN1/SMN2 system anchors the etiology.

Often combines upper and lower motor neuron involvement.

Has sporadic and multiple genetic forms.

Not characterized by the 5q SMN1/SMN2 mechanism.

Slide 54 · A neurogenic biopsy alone cannot classify the disorder

Radiculopathy, peripheral neuropathy, ALS, and SMA can show neurogenic atrophy.

The same downstream morphology can arise from lesions at different positions in the motor pathway.

Anatomic and genetic context therefore change interpretation of similar muscle findings.

Biopsy morphology is one level of evidence within a broader clinicopathologic assessment.

Slide 55 · Mechanism-based therapy: Two approaches

Both described strategies aim to increase availability of functional SMN.

One introduces a working SMN expression source with an adeno-associated viral vector.

The other modifies splicing of SMN2-derived transcripts.

These approaches intervene at different steps of the same causal chain.

Slide 56 · Gene delivery targets the deficient protein source

AAV vector

SMN expression in motor neurons

More SMN protein

Targeting causal deficiency

A gene-delivery strategy; This is a mechanism diagram, not an efficacy or safety claim.

Slide 57 · SMN2 splicing modulation uses the backup gene

SMN2 transcript

Splicing modification

Greater functional SMN output

Therapeutic rationale

Approved genetic therapies that alter processing of SMN2-derived RNA.

Slide 58 · Compare the two therapeutic mechanisms

SMN expression delivery

SMN2 transcript modulation

Introduces a source of functional SMN expression.

Uses an adeno-associated viral delivery system.

Targets the deficit after SMN1 loss.

Acts on RNA processing rather than SMN1 DNA.

Exploits the adjacent SMN2 gene.

Aims to alter the ratio of productive transcript output.

Slide 59 · What cannot be concluded from the treatment paragraph

The textbook paragraph does not provide trial effect sizes or long-term comparative outcomes.

It does not establish a patient-specific sequence of therapies or dosing regimen.

Its quoted acquisition cost is time- and setting-dependent and is not a biologic property.

Mechanistic understanding should be separated from current regulatory and clinical guidance.

Slide 60 · Why timing of therapeutic SMN restoration may matter

Possible early neuron loss

Reduced surviving motor units

Muscle denervation

Residual adaptive capacity

The source notes neuronal loss may begin in utero; A mechanistic inference is that replacing SMN cannot simply resurrect neurons already lost.

Interpretive teaching inference, not an efficacy threshold.

Slide 61 · Case exercise: Severe early motor disorder

A child develops progressive motor weakness during the first year of life. A muscle sample, if examined, is described as showing many markedly small rounded fibers with scattered large survivors.

Which upstream lesion and muscle mechanism connect these observations?

Slide 62 · Case interpretation: Severe infantile pattern

An SMN1 loss-of-function genotype is the causal molecular model of common 5q-SMA.

Marked lower motor neuron loss can start in utero or early after birth.

Absent innervation produces the small rounded myofiber population.

Rare normal or enlarged fibers can be explained by surviving innervation.

Slide 63 · Case exercise: Later childhood weakness

A patient begins to develop motor disability in later childhood. Molecular analysis identifies a disease-associated SMN1 loss-of-function genotype.

How can this be reconciled with a less severe course than infantile SMA?

Slide 64 · Case interpretation: Variable phenotypic severity

The common causal molecular defect can be shared across distinct 5q-SMA phenotypes.

SMN2 copy number influences residual functional SMN protein.

Later onset and a more gradual course are consistent with the textbook description of type III.

A precise prognosis or copy-number threshold cannot be asserted from this vignette alone.

Slide 65 · Case exercise: Neurogenic pathology

A muscle sample shows clusters of similarly typed fibers and regions of atrophy. No genetic data are supplied.

What can morphology establish—and what remains unresolved?

Slide 66 · Case interpretation: Morphology is not etiology

Fiber-type grouping is consistent with collateral reinnervation following denervation.

Grouped atrophy can follow failure of an enlarged reinnervated motor unit.

Several disorders of the motor unit can produce these findings.

A neurogenic pattern alone cannot identify SMN1 loss-of-function.

Slide 67 · High-yield integration: Gene → neuron → myofiber

SMN1 loss-of-function decreases the principal source of survival motor neuron protein.

SMN2 splicing and copy number influence residual functional SMN availability.

Lower motor neuron loss results in denervation and progressive muscle weakness.

Severe infantile muscle demonstrates extensive rounded atrophy and rare enlarged surviving fibers.

Slide 68 · Six interpretive pitfalls to avoid

Common mistake

Correction

SMA is a primary myopathy

Primary lesion is lower motor neuron loss

SMN2 causes all 5q-SMA

SMN1 loss is causal; SMN2 is a modifier

Every atrophic fiber is angular

Infantile SMA can show rounded atrophic fibers

Large fibers exclude denervation

Surviving innervation can produce hypertrophy

Biopsy proves SMN1 etiology

Neurogenic morphology is not gene-specific

Historical outcomes equal treated prognosis

Therapies modify the natural-history context

Slide 69 · Primary reference and source boundaries

Robbins, Cotran & Kumar: Pathologic Basis of Disease

11th edition (2026)

Chapter 28 — Spinal Muscular Atrophy; motor neuron disease context.

Chapter 27 — Neurogenic muscle atrophy and SMA muscle morphology.

For muscle microanatomy, refer to the original textbook description and Figure 27.8; diagrams shown here are explicitly schematic.